Gas-liquid chromatographic assays (GLC) were used to determine the concentrations of gemfibrozil and its metabolites. A known amount of internal standard (heptanoic acid analogue of gemfibrozil) was first added to the sample, which was then acidified, extracted into benzene, backextracted into alkali, reacidified and extracted into chloroform. The dried organic extract was derivatized with bistrimethylsilylacetamide and chromatographed on a 6-foot 3% OV-1 column at 1800C. Quantitation was achieved by comparing the areas under the curves (unknown/ Dr R A Okerholm internal standard) with standard curves (standard/ internal standard).
The samples were also fractionated into 'free' unconjugated gemfibrozil and metabolites which were chromatographed directly on the extracts without earlier enzyme treatment of the specimens, and into 'total' gemfibrozil and metabolites in which the specimens were incubated with glusulase (a mixture of a beta-glucuronidase and an aryl sulfatase) at 37°C for 72 h before extraction. The urinary excretion of these compounds had also stabilized before the radioactive dose.
The plasma levels of non-volatile tritium and 'free' and 'total' gemfibrozil are shown in Fig 6. The levels of non-volatile tritium reached a maximum of 38 ,tg equivalents/ml in 1-2 h and fell with a half-life of 2.3 h through the first 8 h. The gemfibrozil levels reached a maximum of 26 Hg/ml in 1-2 h and fell with a half-life of 1.3 h through 8 h. The plasma levels following withdrawal of the drug reached a maximum of 21 ,g/ ml and 26 ,tg/ml for 'free' and 'total' gemfibrozil respectively in 1-2 h and fell with a half-life of 1.5h.
The urinary and fecal excretion of tritium observed during this study is shown in Fig 7. Urinary excretion was the major route of elimination, and accounted for 65.6 % of the dose in five days. Fiecal excretion accounted for an additional 6% of the dose. Fractionation of the urinary tritium for the first 48 h yielded the data shown in Table 1 . The projected metabolic pathway of gemfibrozil in animals and man is shown in Fig 8. There appear to be three major pathways of gemfibrozil metabolism. The first major pathway is that of conjugation of gemfibrozil and its metabolites. The second major pathway appears to involve hydroxylation of the meta-methyl group of gemfibrozil (Metabolite II), yielding a benzyl alcohol which undergoes rapid oxidation to a benzoic acid metabolite (Metabolite III, the major metabolite). The third pathway appears to involve hydroxylation of the aromatic ring to a phenol (Metabolite 1) which is presumably further metabolized to Metabolite IV, a compound that does not appear to contain an intact carboxylic acid function but which is phenolic in nature. Further studies on the metabolic disposition of gemfibrozil are in progress and will be reported elsewhere.
